GH — Guardant Health, Inc.

Is GH overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Diagnostics & Research

Neutral As of November 17, 2026

Guardant Health, Inc. (GH) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Diagnostics & Research) last closed at $144.03. The rating moved from Oversold to Neutral on November 16, 2026.

AI analysis

Guardant Health is positioned as a leader in liquid biopsy diagnostics with meaningful biopharma partnerships and secular tailwinds from precision oncology and earlier detection. Near-term sentiment is neutral and an 8-K produced no major surprises. Revenue growth prospects hinge on reimbursement progress, successful commercialization of products, and sustained clinical performance. Primary risks include reimbursement uncertainty, competitive pressures, regulatory timing, and execution/cash-burn dynamics. Under favorable reimbursement and adoption scenarios the company can materially expand its addressable market; adverse reimbursement or clinical setbacks would materially constrain upside.

Key factors

  • Market leadership in liquid biopsy and growing adoption of blood-based oncology diagnostics across screening, recurrence monitoring, and therapy selection
  • Expanding partnerships with biopharma for clinical trial assays and companion diagnostics which provide recurring revenue and validation readthroughs
  • Favorable secular demand for minimally invasive cancer diagnostics as standard-of-care shifts toward precision oncology and earlier detection
  • Recent 8-K shows no material negative surprise and social sentiment is neutral—limited short-term headline risk
  • Potential for improved reimbursement clarity in major payors and Medicare pathways that would materially increase addressable market and revenue visibility
  • Operational leverage as volumes scale could accelerate margin improvement if growth is sustained

Risks

  • Reimbursement uncertainty from Medicare and commercial payors that could limit revenue growth or force pricing concessions
  • Intense competition from established diagnostics players and new entrants (other liquid biopsy providers and tissue-based alternatives) affecting market share
  • Clinical performance risks: sensitivity/specificity tradeoffs and real-world validation could slow adoption if results underperform expectations
  • Execution risk: need to scale operations, maintain quality, and convert partnerships into recurring commercial revenue while managing cash burn
  • Regulatory risk around diagnostics and screening approvals which could delay market expansion
  • Macro/market-risk: healthcare sector rotation, changes in risk appetite, or wider market sell-offs could compress multiples and share price volatility

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for GH — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.